The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest

Leukemia

Volumn 30, Issue 12, 2016, Pages 2402-2405

  Locatelli, S L ^a   Careddu, G ^a   Inghirami, G ^b,c,d   Castagna, L ^a   Sportelli, P ^e   Santoro, A ^a,f   Carlo Stella, C ^a,g  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TG Therapeutics Inc   (United States)

^f HUMANITAS UNIVERSITY   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TGR 1202; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ENZYME INHIBITOR; FUSED HETEROCYCLIC RINGS; TGR-1202;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIPROLIFERATIVE ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL DEATH; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IN VIVO STUDY; LETTER; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; MITOSIS; PATHOLOGY;

CELL DEATH; DRUG SYNERGISM; ENZYME INHIBITORS; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MITOSIS; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84984846907     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.224     Document Type: Letter

References (15)

1. Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011; 8: 85-96.
2. Canellos GP. Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma-can they make one of medical oncology's chemotherapy success stories more successful? J Clin Oncol 2012; 30: 2171-2172.
3. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183-2189.
4. Carbone A, Gloghini A, Castagna L, Santoro A, Carlo-Stella C. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. J Pathol 2015; 237: 4-13.
5. Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 2005; 205: 498-506.
6. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117: 591-594.
7. Brown JR. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia. Semin Oncol 2016; 43: 260-264.
8. Deng C, Pan B, O'Connor OA. Brentuximab vedotin. Clin Cancer Res 2013; 19: 22-27.
9. Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL et al. PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012; 119: 1897-1900.
10. Roberts EC, Shapiro PS, Nahreini TS, Pages G, Pouyssegur J, Ahn NG. Distinct cell cycle timing requirements for extracellular signal-regulated kinase and phosphoinositide 3-kinase signaling pathways in somatic cell mitosis. Mol Cell Biol 2002; 22: 7226-7241.
11. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13: 140-156.
12. Burris HA, Patel MR, Fenske TS, O'Connor OA, Deng C, Brander DM et al. TGR-1202, a novel once daily PI3K-delta inhibitor, demonstrates clinical activity with a favorable safety profile, lacking hepatotoxicity, in patients with CLL and B-cell lymphoma [abstract]. Haematologica 2015; 100: 154. Abstract S432.
13. Buttrick GJ, Wakefield JG. PI3-K and GSK-3: Akt-ing together with microtubules. Cell Cycle 2008; 7: 2621-2625.
14. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003; 22: 9075-9086.
15. Blajeski AL, Phan VA, Kottke TJ, Kaufmann SH. G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J Clin Invest 2002; 110: 91-99.